The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Doxatan XL 4 mg Prolonged-release Tablets

4 milligram(s) Prolonged-release tablet

Clonmel Healthcare LtdPA0126/202/004

Main Information

Trade NameDoxatan XL 4 mg Prolonged-release Tablets
Active SubstancesDoxazosin
Strength4 milligram(s)
Dosage FormProlonged-release tablet
Licence HolderClonmel Healthcare Ltd
Licence NumberPA0126/202/004

Group Information

ATC CodeC02CA Alpha-adrenoreceptor antagonists
C02CA04 doxazosin

Status

Authorised/WithdrawnAuthorised
Licence Issued29/07/2005
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0021-008-024
Interchangeable List DocumentPDF of Interchangeable List
« Back